In 2012, Jennifer Doudna and Emmanuelle Charpentier published their ground-breaking paper in Science on programmable CRISPR "genetic scissors". It is not an exaggeration to say that since then every area of molecular biology research has been influenced if not transformed by their remarkable insights. For instance, CRISPR has since been used to expose ‘hiding’ cancer cells to immunotherapy and has even emerged as a technology that may be able to be used to deliver faster COVID-19 tests.
In recognition of their contribution Jennifer Doudna and Emmanuelle Charpentier have been awarded the 2020 Nobel Prize in Chemistry "for the development of a method for genome editing". In the official Nobel press release, chair of the Nobel Committee for Chemistry, Claes Gustafsson, commented that this genetic tool "has not only revolutionised basic science, but also resulted in innovative crops and will lead to ground-breaking new medical treatments".
This award is fantastic news and we are very proud to be involved in protecting Professor Doudna and Charpentier’s revolutionary invention. Mewburn Ellis helped secure the first granted patents in the world for Doudna and Charpentier’s CRISPR technology, and we continue to file and represent patent applications in this growing family of cases before the European Patent Office.
Sign up to our newsletter: Forward - news, insights and features
We have an easily-accessible office in central London, as well as a number of regional offices throughout the UK and an office in Munich, Germany. We’d love to hear from you, so please get in touch.